Aptose receives $2M advance from Hanmi under $8.5M loan facility for tuspetinib AML trial

Aptose Biosciences Inc.

Second advance brings total drawn to $4.5M under the $8.5M loan agreement with Hanmi.
Funds directed to ongoing TUSCANY Phase 1/2 study of tuspetinib triplet therapy in newly diagnosed AML.
Tuspetinib combination with venetoclax/azacitidine showed safety and MRD negativity in early data.
Loan facility announced June 20, 2025; proceeds extend Aptose's cash runway for clinical development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.